|
|
 |
|
 |
 |
 |
 |
 |
Schering-Plough is becoming a new kind of health care company -- dynamic, fast-forward and built on earning trust, every day. As we continue our transformation under a five-phase Action Agenda that began in 2003, we believe that having the right people in the right jobs is critical to advancing our Action Agenda and becoming a high-performance competitor for the long term.
Schering-Plough recognizes and practices four cornerstones for our People Strategy -- attract, develop, engage and reward. We seek to identify and attract people with superior talent, skills and winning attitudes. We are creating an environment of continuous learning to develop our colleagues to the highest levels of performance. We strive to engage colleagues through our unique and inclusive culture where people are energized, excited and committed to shared goals, Values and Leader Behaviors. And, we recognize and reward team members for their contributions to the Company.
By concentrating on these cornerstones, we are building a team of motivated, passionate people with winning attitudes and the right behaviors, skills and experiences to shape their future at Schering-Plough -- and contribute to the Company's success. At Schering-Plough, success begins and ends with our people.
It is a great time to work at Schering-Plough. We are continuing to fill crucial roles with top talent. If our Company's Vision, Values and Mission align with your skills and professional goals, we encourage you to view our open positions. Click here to search job openings.
|
 |
|
 |
 |
 |
 |
 |
 |
| |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
 |
| |
Chairman and CEO:
Fred Hassan |
 |
| |
Number of employees:
55,000 |
 |
 |
| |
Net sales (2007):
$12.7 billion |
 |
 |
| |
Business operations in more than:
140 countries |
 |
| |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
 |
| |
R&D investment
(2007):
$2.9 billion |
 |
| |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
 |
|
 |
 |
 |
|